Ajay Sheshadri, MD, discusses the advantages of attending CHEST 2023 in person and how these benefits can inspire positive change even after the conference ends.
Seeing colleagues in person at the CHEST Annual Meeting 2023 is a valued opportunity after the COVID-19 pandemic and provides advantages for all areas of medicine even after the conference ends, explains Ajay Sheshadri, MD, associate professor of pulmonary medicine at the University of Texas MD Anderson Cancer Center.
Transcript
Why is it beneficial for chest medicine professionals to meet in person at CHEST 2023?
I think we probably took for granted how great it is to see our colleagues in person before the pandemic. During the pandemic, most of our conferences were virtual, and the engagement with the virtual conference is a lot more difficult. You're not there in person seeing the speakers, you're not able to interact with the speakers, other than through a chat box or perhaps a very closely moderated Q&A, and it doesn't quite feel like you're in a research retreat environment.
So, being around people of like-minded interests really just stimulates your own desire to advance the field forward, and I think gives you a lot of energy to be able to motivate yourself when you come back from the conference. Usually, after the conference, there's a little bit of a buzz as you synthesize all the things that you saw and discussed at the conference. To me, that's been incredibly beneficial. Usually after the meetings, there's a flurry of activity and new collaborations and new ideas, and I think you only really get that when you’re there in person and really in the moment.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More